Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.650
0.00 (0.00%)
At close: Jul 6, 2026, 4:00 PM EDT
3.537
-0.113 (-3.08%)
After-hours: Jul 6, 2026, 7:24 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $2.83M in the quarter ending March 31, 2026, a decrease of -39.22%. This brings the company's revenue in the last twelve months to $38.69M, up 7.97% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth.
Revenue (ttm)
$38.69M
Revenue Growth
+7.97%
P/S Ratio
14.48
Revenue / Employee
$444,747
Employees
87
Market Cap
560.14M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Arvinas | 89.40M |
| Assembly Biosciences | 71.10M |
| XOMA Royalty | 48.56M |
| Crescent Biopharma | 11.88M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
EDIT News
- 19 days ago - The Healthcare M&A Wave - Forbes
- 19 days ago - Editas Medicine Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Editas Medicine Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference - GlobeNewsWire
- 5 weeks ago - Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI - TheFly
- 5 weeks ago - TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’ - TheFly
- 5 weeks ago - Editas Medicine 55.6M share Secondary priced at $2.25 - TheFly
- 5 weeks ago - Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering - GlobeNewsWire